Scaffold hopping from pyridones to imidazo[1,2-a]pyridines. New positive allosteric modulators of metabotropic glutamate 2 receptor

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 1, 2010, Pages 175-179

  Tresadern, Gary ^a   Cid, Jose María ^a   Macdonald, Gregor J ^b   Vega, Juan Antonio ^a   de Lucas, Ana Isabel ^a   García, Aránzazu ^a   Matesanz, Encarnación ^a   Linares, María Lourdes ^a   Oehlrich, Daniel ^b   Lavreysen, Hilde ^b   Biesmans, Ilse ^b   Trabanco, Andrés A ^a  

^a JOHNSON AND JOHNSON   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Allosteric; Chemotype hopping; Glutamate; Metabotropic; mGluR2; PAM

Indexed keywords

IMIDAZO[1,2 A]PYRIDINE DERIVATIVE; METABOTROPIC RECEPTOR 2; PYRIDONE DERIVATIVE;

ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG METABOLISM; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION; SUZUKI REACTION;

ALLOSTERIC REGULATION; ANIMALS; HUMANS; IMIDAZOLES; MICROSOMES, LIVER; PYRIDINES; PYRIDONES; RATS; RECEPTORS, METABOTROPIC GLUTAMATE; STATIC ELECTRICITY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 72149094340     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.11.008     Document Type: Article

References (29)

1. Cartmell J., and Schoepp D.D. J. Neurochem. 75 (2000) 889
2. Swanson C.J., Bures M., Johnson M.P., Linden A.M., Monn J.A., and Schoepp D.D. Nat. Rev. Drug Disc. 4 (2005) 131
3. Schoepp D.D., and Marek G.J. Curr. Drug Targets: CNS Neurol. Disord. 1 (2002) 215
4. Levine L., Gaydos B., Sheehan D., Goddard A., Feighner J., Potter W., and Schoepp D.D. Neuropharmacology 43 (2002) 294
5. Patil S.T., Zhang L., Martenyi F., Lowe S.L., Jackson K.A., Andreev B.V., Avedisova A.S., Bardenstein L.M., Gurovich I.Y., Morozova M.A., Mosolov S.N., Neznanov N.G., Reznik A.M., Smulevich A.B., Tochilov V.A., Johnson B.G., Monn J.A., and Schoepp D.D. Nat. Med. 13 (2007) 1102
6. Fell M.J., Svensson K.A., Johnson B.G., and Schoepp D.D. J. Pharmacol. Exp. Ther. 326 (2008) 209
7. Jeffrey Conn P., Christopoulos A., and Lindsley C.W. Nat. Rev. Drug Disc. 8 (2009) 41
8. Compound 3:. Barda D.A., Wang Z.Q., Britton T.C., Henry S.S., Jagdmann G.E., Coleman D.S., Johnson M.P., Andis S.L., and Schoepp D.D. Bioorg. Med. Chem. Lett. 14 (2004) 3099
9. compound 4:. Pinkerton A.B., Cube R.V., Hutchinson J.H., Rowe B.A., Schaffhauser H., Zhao X., Daggett L.P., and Vernier J.M. Bioorg. Med. Chem. Lett. 14 (2004) 5329
10. compound 5:. Pinkerton A.B., Cube R.V., Hutchinson J.H., James J.K., Gardner M.F., Rowe B.A., Schaffhauser H., Rodriguez D.E., Campbell U.C., Daggett L.P., and Vernier J.M. Bioorg. Med. Chem. Lett. 15 (2005) 1565
11. compound 6: Empfield, J.; Folmer, J. WO2007/095024 A1
12. compound 7: Balestra, M.; Bunting, H; Chen, D.; Egle, I.; Forst, J.; Frey, J.; Isaac, M.; Ma, F.; Nugiel, D.; Slassi, A.; Steelman, G.; Sun, G.; Sundar, B.; Ukkiramapandian, R.; Urbanek, R.; Walsh, S. WO2006/071730 A1
13. compound 8: Cid-Nuñez, J. M.; Andrés-Gil, J.; Trabanco-Suárez, A. A., Oyarzábal-Santamarina, J.; Dautzenberg, F.; Macdonald, G.; Pullan, S.; Lutjens, R.; Duvey, G.; Nhem, V.; Finn, T.; Melikyan, G. WO2007/104783 A1
14. compound 9:. Zhang L., Rogers B.N., Duplantier A.J., McHardy S.F., Efremov I., Berke H., Qian W., Zhang A.Q., Maklad N., Candler J., Doran A.C., Lazzaro J., and Ganong A.H. Bioorg. Med. Chem. Lett. 18 (2008) 5493
15. compound 10:. Duplantier A.J., Efremov I., Candler J., Doran A.C., Ganong A.H., Haas J.A., Hanks A.N., Kraus K.G., Lazzaro J., Lu J., Maklad N., McCarthy S.A., O'Sullivan T.J., Rogers B.N., Siuciak J.A., Spracklin D.K., and Zhang L. Bioorg. Med. Chem. Lett. 19 (2009) 2524
16. Recasens M., Guiramand J., Aimar R., Abdulkarim A., and Barbanel G. Curr. Drug Targets 8 (2007) 651
17. Gjoni T., and Urwyler S. Neuropharmacology 55 (2008) 1293
18. Lorrain D.S., Schaffhauser H., Campbell U.C., Baccei C.S., Correa L.D., Rowe B., Rodriguez D.E., Anderson J.J., Varney M.A., Pinkerton A.B., Vernier J.M., and Bristow L.J. Neuropsychopharmacology 28 (2003) 1622
19. Galici R., Jones C.K., Hemstapat K., Nong Y., Echemendia N.G., Williams L.C., de Paulis T., and Conn P.J. J. Pharmacol. Exp. Ther. 318 (2006) 173
20. Chemical Computing Group Inc. Molecular Operating Environment (MOE), 1010 Sherbrooke St. W, Suite 910, Montreal, QC, Canada; available from Chemical Computing Group Inc. at http://www.chemcomp.com. 2009.
21. 50 of 6.6.
22. Oyarzábal J., Howe T., Alcazar J., Andrés J.I., Alvarez R.M., Dautzenberg F., Iturrino L., Martínez S., and Van der Linden I. J. Med. Chem. 52 (2009) 2076
23. OMEGA. OpenEye Scientific Software, Inc.; http://www.eyesopen.com. 2006.
24. Grant J.A., Gallardo M.A., and Pickup B.T. J. Comput. Chem. 17 (1996) 1653
25. Nicholls A., MacCuish N.E., and MacCuish J.D. J. Comput. Aided Mol. Des. 18 (2004) 451
26. Trabanco-Suárez A. A.; Tresadern G. J.; Vera-Ramiro J. A.; Cid-Nuñez J. M. WO2009/062676 A2.
27. 20) was characterized using a CHO cell line expressing the human mGluR2 receptor. See Ref. 19 for a detailed description of this assay.
28. The calculated Alog P for 16c-f were 1.2, 1.6, 2.0 and 1.6, respectively, and 1.8, 2.2 and 2.2 for 16g-i.
29. 35S]-GTPγS functional assays.